```html

Xanthic Keratopathy: A Complete Patient‑Friendly Guide

Overview

Xanthic keratopathy (also called corneal xanthoma or yellow‑white corneal deposits) is a rare, non‑infectious disorder in which yellow‑brown lipid‑laden deposits accumulate within the corneal stroma. The deposits give the cornea a characteristic “golden” or “xanthic” appearance and can lead to visual disturbances when they interfere with light transmission.

Because the condition is uncommon, exact prevalence data are limited. Case series from tertiary eye centers suggest an incidence of fewer than 1 in 100,000 people worldwide, with most reports originating from ophthalmology clinics that manage patients with systemic lipid disorders or certain genetic syndromes [1] Mayo Clinic. The disease can affect any age group, but two patterns are recognized:

• Acquired form: Most often seen in adults with systemic hyperlipidemia, liver disease, or after intra‑ocular medication use.
• Hereditary form: Linked to rare genetic conditions such as familial hypercholesterolemia, Tangier disease, or the Ocular‑Lipid‑Deposits syndrome; it may present in children or adolescents.

Symptoms

Symptoms vary according to the size, depth, and location of the deposits. Early disease can be asymptomatic and discovered only during a routine eye exam.

Common ocular symptoms

• Blurred or hazy vision: The deposits scatter light, especially when they involve the central visual axis.
• Glare and photophobia: Bright lights may cause discomfort because the cornea loses its normal transparency.
• Reduced contrast sensitivity: Fine details (e.g., reading small print) become harder to discern.
• Eye irritation or foreign‑body sensation: Some patients describe a gritty feeling.
• Redness: Usually mild, caused by surface irritation.

Systemic clues that may accompany the ocular signs

• Yellowish plaques on the skin (xanthomas) of elbows, knees, or tendons.
• History of high cholesterol, especially LDL‑cholesterol > 190 mg/dL.
• Liver dysfunction, gallstones, or pancreatitis (often linked to hypertriglyceridemia).
• Family history of lipid disorders or early cardiovascular disease.

Causes and Risk Factors

At its core, xanthic keratopathy results from the deposition of lipid‑rich material in the corneal stroma. Several pathways can lead to this:

Acquired causes

• Severe hyperlipidemia: Elevated serum LDL, VLDL, or triglycerides increase the amount of circulating cholesterol that can leak into corneal tissue.
• Systemic diseases:
  • Familial hypercholesterolemia (FH) – autosomal‑dominant mutation in the LDL‑R, APOB, or PCSK9 genes.
  • Tangier disease – deficiency of the ABCA1 transporter leading to extremely low HDL and massive lipid accumulation.
  • Liver cirrhosis or cholestasis – impaired lipid metabolism.
• Medication‑induced: Long‑term use of topical steroids, topical cyclosporine, or certain systemic drugs (e.g., tamoxifen) has been linked to corneal lipid deposits.
• Ocular trauma or surgery: Persistent inflammation may disrupt the corneal endothelial barrier, allowing lipids to seep in.

Hereditary / genetic factors

• Rare autosomal‑recessive disorders such as Familial Chylomicronemia Syndrome (LPL deficiency).
• Syndromic conditions (e.g., Hartnup disease, abetalipoproteinemia) that cause systemic lipid abnormalities.

Risk factors

• Uncontrolled high LDL‑cholesterol or triglyceride levels.
• Family history of FH or other lipid disorders.
• Obesity, metabolic syndrome, or type 2 diabetes mellitus.
• Chronic use of corticosteroid eye drops (≥ 3 months).
• Age > 40 years for the acquired form (though genetic forms appear earlier).

Diagnosis

Diagnosing xanthic keratopathy relies on a combination of clinical examination, imaging, and laboratory testing to rule out mimickers such as corneal dystrophies or infiltrative infections.

Clinical eye examination

• Slit‑lamp biomicroscopy: Reveals yellow‑brown, granular to confluent deposits, typically beginning in the peripheral stroma and occasionally migrating centrally.
• Fluorescein staining: Usually negative (intact epithelium), helping differentiate from epithelial erosions.

Imaging modalities

• Anterior segment optical coherence tomography (AS‑OCT): Shows hyper‑reflective layers within the stromal depth; useful for monitoring progression.
• In‑vivo confocal microscopy: Provides cellular‑level detail, confirming lipid vacuoles within keratocytes.
• Corneal topography: May reveal irregular astigmatism if central deposits are extensive.

Laboratory work‑up

• Fasting lipid panel (total cholesterol, LDL‑C, HDL‑C, triglycerides).
• Liver function tests (ALT, AST, GGT, bilirubin) if hepatic disease is suspected.
• Genetic testing (e.g., LDLR, PCSK9, APOB, ABCA1) for hereditary hyperlipidemia when a familial pattern is evident.

Differential diagnosis

Key conditions to exclude include: corneal arcus, Schnyder corneal dystrophy, band keratopathy, Rose Bengal‑positive infiltrates, and infectious keratitis. A detailed history and appropriate imaging usually differentiate these entities.

Treatment Options

Therapeutic goals focus on (1) halting further lipid deposition, (2) improving visual acuity, and (3) addressing underlying systemic disease.

Systemic lipid‑lowering therapy

• Statins (e.g., atorvastatin, rosuvastatin): First‑line agents that reduce LDL‑C by 30‑50 %.
• Ezetimibe: Blocks intestinal cholesterol absorption; useful when statins alone are insufficient.
• PCSK9 inhibitors (evolocumab, alirocumab):** For patients with familial hypercholesterolemia who cannot achieve targets with oral agents.
• Fibrates (gemfibrozil, fenofibrate): Primarily lower triglycerides; considered in mixed dyslipidemias.
• Omega‑3 fatty acid supplements: Modest triglyceride‑lowering effect and cardiovascular benefit.

Guidelines from the American College of Cardiology/AHA recommend aiming for LDL‑C < 70 mg/dL in high‑risk patients [2] ACC/AHA 2019 Guideline. Reaching these targets often leads to regression of corneal lipid deposits over months to years.

Topical and ocular therapies

• Discontinuation of chronic steroid eye drops: Replace with preservative‑free lubricants or cyclosporine 0.05 % if inflammation persists.
• Lubricating eye drops (artificial tears): Reduce surface irritation and improve comfort.
• Topical corticosteroid taper (short course): Occasionally used to control active inflammatory component, but must be stopped promptly to avoid worsening lipid deposition.

Surgical / procedural interventions

• Phototherapeutic keratectomy (PTK): Excimer laser removal of superficial deposits; improves visual acuity when central deposits are limiting vision.
• Deep anterior lamellar keratoplasty (DALK): Reserved for advanced cases where deposits are deep and vision is severely compromised.
• Corneal collagen cross‑linking (CXL): Not a primary treatment for xanthic keratopathy but may be combined with PTK when corneal stability is a concern.

Lifestyle modifications

• Adopt a heart‑healthy diet (Mediterranean style, < 30 % calories from fat, saturated fats < 7 %).
• Exercise ≥ 150 min/week of moderate‑intensity aerobic activity.
• Weight management – aim for BMI < 25 kg/m².
• Avoid smoking and excessive alcohol intake.

Living with Xanthic Keratopathy

Even with treatment, many patients live with residual corneal opacity. The following strategies help maintain visual function and eye comfort.

Vision optimisation

• Regular refraction checks: Updating glasses or contact lenses can compensate for induced astigmatism.
• Anti‑glare lenses or photochromic coatings: Reduce photophobia.
• Low‑vision aids: Magnifiers or electronic reading devices for those with persistent central haze.

Protecting the ocular surface

• Use preservative‑free artificial tears at least 4–6 times daily.
• Wear sunglasses with 100 % UV protection outdoors.
• Avoid dusty or windy environments; use protective goggles if necessary.

Follow‑up schedule

• Every 3–6 months: Comprehensive eye exam with slit‑lamp and OCT to track deposit regression.
• Annually: Full lipid panel and cardiovascular risk assessment.

Psychosocial considerations

Some patients may feel self‑conscious about the yellowish appearance of the eyes. Counseling, support groups for rare eye diseases, or discussion with a low‑vision specialist can be beneficial.

Prevention

Because most cases are linked to systemic lipid abnormalities, primary prevention focuses on cardiovascular health.

• Screen family members for hyperlipidemia if a hereditary disorder is identified.
• Maintain LDL‑C and triglyceride levels within guideline‑recommended ranges.
• Promptly treat liver disease, diabetes, or metabolic syndrome.
• Limit long‑term use of topical steroids; seek alternative anti‑inflammatory eye drops when possible.

Complications

If left untreated or if lipid control is inadequate, the following complications may arise:

• Progressive visual loss: Central stromal involvement can lead to permanent reduction in best‑corrected visual acuity.
• Corneal scarring: Chronic deposits may trigger fibro­blastic activity, causing irreversible opacity.
• Secondary glaucoma: Rarely, extensive deposits may impede aqueous outflow.
• Systemic cardiovascular events: The same dyslipidemia that drives corneal deposits also raises the risk of myocardial infarction and stroke.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Xanthoma of the cornea.” Updated 2023. https://www.mayoclinic.org
2. American College of Cardiology/American Heart Association. 2019 Guideline on the Primary Prevention of Cardiovascular Disease. https://www.acc.org
3. National Eye Institute. “Corneal Dystrophies and Disorders.” 2022. https://nei.nih.gov
4. Cleveland Clinic. “Hyperlipidemia: Causes, Symptoms, and Treatment.” 2024. https://my.clevelandclinic.org
5. World Health Organization. “Noncommunicable diseases: Cardiovascular disease.” 2023. https://www.who.int

```